Immunic, inc. announces closing of oversubscribed $65 million underwritten public offering

New york , june 3, 2025 /prnewswire/ -- immunic, inc. ("immunic" or the "company") (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "pre-funded warrants"), (ii) series a warrants to purchase shares of common stock (or pre-funded warrants) (the "series a warrants"), and (iii) series b warrants to purchase shares of common stock (or pre-funded warrants) (the "series b warrants"). the pre-funded warrants are immediately exercisable, and may be exercised at any time after their original issuance.
IMUX Ratings Summary
IMUX Quant Ranking